Researcher Challenges DEA Over Unlawful Marijuana Rescheduling Tactics

A monumental legal battle has begun, led by researcher David Heldreth, against none other than the Drug Enforcement Administration (DEA)—an agency clinging tightly to its archaic control over cannabis, a plant that once paid the taxes it’s now taxed for. Heldreth’s case raises critical questions on the DEA’s convoluted, exclusionary approach to rescheduling marijuana, which impacts millions of lives, countless small businesses, and sovereign Native American tribes, while appearing to favor big industry players. This lawsuit may be the showdown cannabis advocates have waited for, calling out the DEA’s sketchy, opaque decision-making.

Heldreth is far from a bystander; he’s the CEO of Panacea Plant Sciences, a company dedicated to groundbreaking cannabis and psychedelic research, and now, the plaintiff in this high-profile case. His fight is not just against bureaucratic injustice but for the constitutional right to grow and consume cannabis without persecution—a freedom that, if regulatory bodies had their way, would be lost to red tape. In his suit, Heldreth seeks injunctive relief to stop the DEA’s restrictive rescheduling process, citing a list of alleged legal violations. This case represents not only a push for transparency but also a stand for the rights of smaller entities and indigenous groups sidelined by a system designed to drown their voices.

Behind the DEA’s Rescheduling Controversy

• Researcher David Heldreth challenges the DEA’s exclusionary rulemaking process for cannabis rescheduling, spotlighting alleged favoritism toward big industry players.
• The lawsuit accuses the DEA of bypassing mandatory consultations with Native American tribes and small businesses, violating federal requirements.
• Moving cannabis to Schedule III could lift IRS restrictions, letting cannabis businesses deduct operating expenses—a game-changer for industry profitability.
• DEA’s selective participation list, which excludes critics, raises questions about bias and transparency in the rulemaking process.
• The case has potential to reshape cannabis policy, pushing for fairer laws that respect the voices of small businesses, Native communities, and individuals.

DEA’s Marijuana Rescheduling Process Background and Recent Actions

Cannabis has lingered on the Controlled Substances Act as a Schedule I substance for far too long, positioned with drugs deemed to have “no accepted medical use.” But as public demand swells for full access and recognition of marijuana’s medical benefits, the federal government has been forced to acknowledge that its Schedule I classification may be more of a political weapon than a scientifically based policy. Following President Biden’s 2022 directive, federal agencies, led by the Department of Health and Human Services (HHS), recommended reclassifying marijuana to Schedule III, which DEA finally agreed to consider.

This rescheduling would mean cannabis could be treated similarly to anabolic steroids and ketamine—drugs with accepted medical uses and moderate abuse potential. It would also lift restrictions on the cannabis industry’s ability to deduct business expenses under IRS Section 280E, a financially crippling rule that applies solely to Schedule I and II substances. Small businesses could finally breathe easier and operate without the financial strangulation imposed by current laws.

But let’s not forget how the DEA is handling this transition. The agency opened a public comment period in early 2024, collecting 43,000 responses from diverse sectors, yet it has consistently sidelined voices like those of Panacea Plant Sciences and Native American representatives. The cherry-picked list of approved participants, chosen by DEA Administrator Anne Milgram, seems to ignore both the industry’s backbone—small businesses—and key community stakeholders, showing the agency’s clear preference for large corporate players. These aren’t “comments” the DEA is sifting through; they’re pre-screened monologues that reinforce its pre-existing biases.

Heldreth’s Legal Claims Against the DEA

David Heldreth isn’t going after the DEA on just one front. His complaint highlights a range of legal missteps that reveal the DEA’s highly questionable ethics. Here are his primary allegations:

• Ignoring Tribal Consultations: Despite the clear impact federal marijuana scheduling has on Native American tribal law, the DEA bypassed Executive Order 13175, which mandates federal agencies consult tribes on actions that affect them. For tribes with sovereign rights to self-govern, this lack of consultation is not just disrespectful; it’s an outright violation of federal obligations.
• Shutting Out Small Businesses: Small businesses like Panacea Plant Sciences, which don’t hold Schedule III licenses, face systemic disadvantages from this rulemaking process. The DEA’s rulemaking approach seems to tailor benefits toward large, licensed organizations, effectively pushing smaller cannabis operations out of the conversation. Heldreth argues this disregard violates the Regulatory Flexibility Act (RFA) and Small Business Regulatory Enforcement Fairness Act (SBREFA), which protect small entities from exclusion.
• Punitive Exclusion of Critic Voices: The DEA’s selective hearing list excluded Heldreth and his company despite their timely requests to participate. Heldreth sees this as retaliation, a blatant effort by DEA Administrator Milgram to silence critics who oppose her restrictive scheduling decisions. The administrative bias is almost palpable—a gatekeeper of cannabis law shutting doors on anyone who dares question her authority.

Why Rescheduling Matters Tax and Business Implications

The decision to shift marijuana from Schedule I to Schedule III isn’t merely symbolic; it’s a significant economic game-changer, especially for businesses under IRS scrutiny. Currently, Section 280E bars cannabis-related companies from deducting business expenses, making profitability a near-impossible task. Moving to Schedule III, however, would eliminate these restrictions, allowing cannabis businesses to finally operate under fairer tax codes and reinvest in growth, employee benefits, and community initiatives.

A Schedule III classification acknowledges what cannabis users and advocates have long known: marijuana has valid, medicinal uses and a far lower risk of abuse than pharmaceuticals. And while the DEA’s slow-motion approval process drags on, each day that businesses remain shackled by IRS rules is another day of lost opportunities. For an industry that’s created thousands of jobs, improved countless lives, and contributed significantly to state economies, the inability to fully deduct operational expenses under IRS regulations is a form of financial handcuffing designed to benefit no one but the government.

But this begs the question: Why not deschedule cannabis entirely? Moving it to Schedule III is still a form of federal control, maintaining the DEA’s grip over an industry that doesn’t require their “protection.” By easing these tax and operational restrictions, we’d see the kind of economic boost that communities and small business owners deserve.

DEA’s Alleged Bias and Retaliation Against Critics

The DEA’s behavior in this rescheduling process doesn’t just appear biased; it is a textbook example of administrative retaliation against dissenting voices. The agency, rather than embracing feedback from various stakeholders, has excluded any group daring to demand transparency or advocate for public interest. DEA Administrator Milgram’s decision to exclude critics like Heldreth and Native American representatives is a clear message: dissent will not be tolerated.

This action isn’t just a show of force by the DEA; it’s a rejection of the principles of open rulemaking. By excluding groups with standing and including only voices that align with the DEA’s agenda, the agency reveals a preference for favorable opinions over actual public engagement. Even the DEA’s own Chief Administrative Law Judge expressed doubt regarding the standing of several pre-approved participants, indicating that these were hardly the most qualified or affected parties. But, as the DEA demonstrates time and again, their process isn’t about qualification or concern—it’s about control.

Legal Violations and Constitutional Challenges Cited by Heldreth

The foundation of Heldreth’s lawsuit is built on undeniable legal violations by the DEA, from trampling over consultation rights to unconstitutional actions concerning Administrative Law Judges (ALJs). He argues that the DEA’s refusal to consult with Native American tribes violates Executive Order 13175, a law protecting tribal sovereignty, and that its disregard for small businesses under the RFA puts hundreds of entities at a disadvantage. These violations aren’t simply “oversights”—they’re strategic, discriminatory actions that side-step legal obligations.

Further compounding these issues is the constitutionality of the DEA’s ALJs. Heldreth contends that the appointment of ALJs without proper adherence to Article II of the Constitution is grounds for serious concern. In 2018, the Supreme Court clarified that ALJs must be appointed by heads of departments or the President to uphold the integrity of the judiciary. Yet, DEA’s ALJs exist under questionable authority, with removal restrictions that leave them unaccountable to executive oversight. In essence, these judges operate under the DEA’s thumb—hardly the model of impartiality required for such critical decision-making.

Potential Outcomes and Broader Impact on Marijuana Policy

If Heldreth’s case succeeds, it could halt the DEA’s rulemaking and force a reevaluation of federal marijuana laws. This isn’t just about one researcher’s right to participate in a hearing; it’s about safeguarding a fair process that respects the rights of all stakeholders. The implications extend far beyond this case, potentially influencing future federal cannabis policies and opening doors to a more inclusive rulemaking process.

The outcome of this legal battle could either reaffirm the DEA’s authority to push its agenda unchecked or set a precedent that holds federal agencies accountable for respecting tribal, small business, and individual rights. In the grander scope, this could be the catalyst needed to push for full de-scheduling of marijuana, paving the way for legalized, regulated, and fairly taxed cannabis nationwide.

Final Thoughts A Call for Transparent and Fair Rulemaking

As Heldreth’s case against the DEA unfolds, it’s clear that this is more than a battle over participation rights—it’s a fight for fairness in the cannabis industry. The days of outdated, bureaucratic control over a plant that has been used by humans for centuries should be behind us. Cannabis isn’t just an industry; it’s a cultural, spiritual, and medicinal revolution.

When regulatory bodies prioritize big industry voices over community stakeholders and small businesses, they undermine the very foundation of democracy. If the DEA truly believes in serving the public, it’s time they prove it by holding open and inclusive rulemaking sessions that welcome all voices—not just those that support their agenda.